Clinical features of Hirayama disease in mainland China
Bo Zhou(Chinese Academy of Sciences), Dong Zhou, Dongsheng Fan(King University), Lei Chen(Zhuzhou Central Hospital)
Cited by 10
Related Papers
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Stroke in China: advances and challenges in epidemiology, prevention, and management
|The Lancet Neurology|2019|1.6k
Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction
|Journal of Clinical Oncology|2016|1k
Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma
|New England Journal of Medicine|2019|934
Estimated Burden of Stroke in China in 2020
|JAMA Network Open|2023|595